Clinical Trials Logo

Pancreatic Neuroendocrine Tumor clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumor.

Filter by:

NCT ID: NCT00942682 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.

NCT ID: NCT00804336 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR. Sandostatin is an approved drug for the use of treating symptoms of neuroendocrine tumors. SOM230 has shown to be effective in patients who have become resistant to Sandostatin and may also stop cancer cells from growing. RAD001 is an investigational drug that also may stop cancer cells from growing.

NCT ID: NCT00576680 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This research study will test the safety of RAD001 in combination with temozolomide.

NCT ID: NCT00428220 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.